(MENAFN- Investor Brand Network) early last year acquired PRV-002, a drug candidate for concussed patients to mitigate both short-term and long-term consequences of concussion. Concussion or mTBI“is caused by a jolt, blow or force to the head that changes the brain's function. This change often results in myriad consequences ranging from emotional and somatic changes to cognitive impairment and physical symptoms… In most cases, concussion symptoms resolve within a few days or weeks as the damaged pathways rebuild and strengthen through repetition, use and cleanup of cell debris. However, there has been growing concern that mTBI may be associated with long-term consequences, particularly due to repeated or multiple head impacts,” explains a recent article.“Odyssey has so far evidenced, through animal studies, that PRV-002 can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation caused by concussion while simultaneously restoring proper blood flow. The drug is intended to be administered immediately after a concussive episode, effectively mitigating the effects a blow or jolt might have on the brain and its functions.”
To view the full article, visit
About Odyssey Health Inc.
Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information about the company, visit .
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company's newsroom at
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text“Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
BioMedWire (BMW)
San Francisco, California
415.949.5050 Office
BioMedWire is part of the